Difference between revisions of "Team:SCUT-China B/HP/Gold"

Line 519: Line 519:
 
<body>
 
<body>
 
     <div class="nav">
 
     <div class="nav">
         <li><img src="https://static.igem.org/mediawiki/parts/3/3b/Wiki_logo.png" alt="logo" class="logo1"></li>
+
         <li style="width:10%;"><img src="https://static.igem.org/mediawiki/parts/3/3b/Wiki_logo.png" alt="logo" class="logo1"></li>
 
         <li><img src="https://static.igem.org/mediawiki/parts/6/6a/Wiki_4.png" alt="logo" class="logo2"></li>
 
         <li><img src="https://static.igem.org/mediawiki/parts/6/6a/Wiki_4.png" alt="logo" class="logo2"></li>
         <li><a href="../home.html">Home</a></li>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B">Home</a></li>
         <li><a href="overview.html">Project</a>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B/Overview">Project</a>
             <ul>
+
             <ul class="ultop">
                 <li><a href="overview.html">Overview</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Overview">Overview</a></li>
                 <li><a href="propoptosis.html">Apoptosis Induction</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Propoptosis">Apoptosis Induction</a></li>
                 <li><a href="protumor.html">Tumor specific promoter</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Protumor">Tumor specific promoter</a></li>
 
             </ul>
 
             </ul>
 
         </li>
 
         </li>
         <li><a href="">Achievements</a>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B/Results">Achievements</a>
             <ul>
+
             <ul class="ultop">
                 <li><a href="">Results</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Results">Results</a></li>
                 <li><a href="parts.html">Parts</a></li>               <li><a href="">Judging</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Parts">Parts</a></li>
 +
                <li><a href="https://2016.igem.org/Team:SCUT-China_B/Judging">Judging</a></li>
 
             </ul>
 
             </ul>
 
         </li>
 
         </li>
         <li><a href="modeling.html">Modeling</a>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B/Modeling">Modeling</a>
             <ul>
+
             <ul class="ultop">
                 <li><a href="apoptosis.html">Apoptosis</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Apoptosis">Apoptosis</a></li>
                 <li><a href="crispri.html">CRISPRi/a</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Crispri">CRISPRi/a</a></li>
 
             </ul>
 
             </ul>
 
         </li>
 
         </li>
         <li><a href="">Notebook</a>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B/Protocol">Notebook</a>
             <ul>
+
             <ul class="ultop">
                 <li><a href="Protocol.html">Protocol</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Protocol">Protocol</a></li>
                 <li><a href="Safety.html">Safety</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Safety">Safety</a></li>
 
             </ul>
 
             </ul>
 
         </li>
 
         </li>
         <li><a href="hp.html">Human Practice</a>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/Gold">Human Practice</a>
             <ul>
+
             <ul class="ultop">
                 <li><a href="hp.html">Overview</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/Gold">Overview</a></li>
                 <li><a href="hp1.html">Project Design</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/HP1">Project Design</a></li>
                 <li><a href="hp2.html">Hospice Care</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/HP2">Public Outreach</a></li>
                 <li><a href="hp3.html">Public Outreach</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/HP3">Hospice Care</a></li>
 
             </ul>
 
             </ul>
 
         </li>
 
         </li>
         <li><a href="">Lab</a>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B/Team">Lab</a>
             <ul>
+
             <ul class="ultop">
                 <li><a href="team.html">Team</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Team">Team</a></li>
                 <li><a href="Collaborations.html">Collaborations</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Collaborations">Collaborations</a></li>
                 <li><a href="Attributions.html">Attributions</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Attributions">Attributions</a></li>
 
             </ul>
 
             </ul>
 
         </li>
 
         </li>

Revision as of 18:04, 28 November 2016

IGEM-China_B

overview

This year the theme of our project is gene therapy for lung adenocarcinoma. Our human practice was tightly connected with the project and had been a push to our project. We attended seminar about oncotherapy, interviewed doctors and stuffs from famous cancer hospital in Guangzhou and learnt about modern tumour therapies. All the experiences above enabled us to improve the design of our experiment and complete our project so that it could fit clinical need in hospital. We also extended our project to hospice care as a part of our human practice. We believed that all our efforts in developing new lung adenocarcinoma therapy was patient-centered so we thought about providing physical and psychological care for patients who were told unlikely be cured by relieving their pain and grief. We hoped every patient with terminal stage disease could pass away with peace. This purpose requires a more developed hospice care system and we believed we had worked hard to make our contribution. Another important part of our human practice was promotion of synthetic biology. We wanted the public to become aware of synthetic biology and we hoped this rising technology could soon enough to benefit the society.